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ABSTRACT

Research Study to Reduce Opioid Medication Use in Chronic Pain
Patients by Adding Memantine: A Pilot Study
Adam J. Bertino, B.S.
Masters in Biomedical Sciences, July 2017
Philadelphia College of Osteopathic Medicine
Frederick J. Goldstein, PhD, Thesis Adviser

An investigational clinical research pilot study is being conducted at a nursing
facility and an academic primary care office to evaluate memantine as an adjunct to
opioid therapy for treatment of chronic pain. Memantine can be beneficial in reducing
pain because it is an N-methyl-D-aspartate receptor (NMDAr) antagonist with a pivotal
action in the hippocampus: it initiates long-term potentiation in the anterior cingulate
cortex and forebrain. These areas of action have a high probability for reducing the
affective quality of pain.
This open-label, non-randomized pilot study is designed to observe any effects
which may occur during addition of memantine to the therapeutic regimen of nursing
home patients and office patients who take daily opioids (oxycodone,
oxycodone/acetaminophen combination or hydromorphone) on an as-needed basis (prn)
for chronic pain. The objective is to gauge, preliminarily, whether patients benefit from
using memantine as an adjunct to their daily oxycodone/acetaminophen or
hydromorphone treatment by increased analgesia, a reduction of opioid used, and
increased bowel movements.
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Memantine efficacy was assessed using pain diaries where patients recorded on a
daily basis the amount of opioid used, pain scores (from ‗0‘ [no pain] to ‗10‘ [worst pain
ever]), and number of bowel movements. Data are collected for six weeks; initially a twoweek, no-memantine observation period, followed by a four-week treatment phase.
Collected data are then analyzed.
With the first patient to complete the study, a trend of decreased pain scores over
the six-week study was observed. There was also an indication of decreased opioid use
but may be due to inconsistencies; bowel movements fluctuated and did not show a trend.
The second patient showed trends of a decreased pain score with a decrease in opioid
dosage over the course of the study and slightly lower bowel movements per week.
This pilot study presented insight to the plausible use of memantine as an adjunct
to treat chronic pain patients. Although the number of patients that participated in this
pilot was small, the trends observed may help to launch this type of study into a larger
scale. Thus, these initial data present insight to the plausible use of memantine as an
adjunct to treat chronic non-malignant pain patients who take an opioid daily.

v

TABLE OF CONTENTS

LIST OF FIGURES……………………………………………….………….……..ix
AKNOWLEDGEMENTS……...………………….………….……………..……...xiv
Chapter 1. INTRODUCTION……………………………..……………………........1
Chapter 2. METHODS…………………………………..………………………..…12
Chapter 3. RESULTS: INCOMPLETE PATIENTS……………………..….……..18
3.1. PART A…………………………………………..…………………..….……..18
3.1.1. Study Subject M-02-B………………………..…………………..….……....18
3.1.2. Study Subject M-03-B………………………..…………………..….…..…..20
3.1.3. Study Subject M-04-B………………………..…………………..….…..…..21
Chapter 4. RESULTS: COMPLETE PATIENTS………..…………………………22
4.1 PART B………………………..…………………..…………………….….…..23
4.1.1. Study Subject M-01-B………………………..…………………..…..….…..23
4.1.1.1. Overview of Week Zero…..…………………..…………………….……..24
4.1.1.2. Pre-Memantine Phase……………………..…………………..…..…..…..25
4.1.1.2.1. Pain Scores……………..…………………..…………………….….…..26
4.1.1.2.2. Oxy/acet Dosage…………………………….………………..…..……..29
4.1.1.2.3 Bowel Movements..……..…………………..…………………….……..30
4.1.1.2.4. Overview of Pre-Memantine Phase……..…………………..…..…..…..31
4.1.1.3. Week One of Memantine…..…………………..…………………...……..32
4.1.1.3.1. Pain Scores……….………………………..…………………..…….…..32
4.1.1.3.2. Oxy/acet Dosage………..…………………..…………………….……..33
4.1.1.3.3. Bowel Movements……………………..…………………..…..…..…...34
4.1.1.3.4. Overview through Week One of Memantine.…………………………..35

vi

4.1.1.4. Week Two of Memantine…………………….………………..…..…………..35
4.1.1.4.1. Pain Scores……….………………………..…………………..……………..36
4.1.1.4.2. Oxy/acet Dosage………..…………………..…………………….……..…..38
4.1.1.4.3. Bowel Movements……………………..…………………..…..………..…..39
4.1.1.4.4. Overview through Week Two of Memantine.………………………..……..40
4.1.1.5. Week Three of Memantine…..…………………..…………………..….……..40
4.1.1.5.1. Pain Scores……….………………………..…………………..……………..41
4.1.1.5.2. Oxy/acet Dosage………..…………………..………………………………..43
4.1.1.5.3. Bowel Movements……………………..…………………..…..………..…..44
4.1.1.5.4. Overview through Week Three of Memantine.……………………....……..44
4.1.1.6. Week Four of Memantine…………………….………………..……….……..45
4.1.1.6.1. Pain Scores……….………………………..…………………..……...……..45
4.1.1.6.2. Oxy/acet Dosage………..…………………..…………………….……..…..47
4.1.1.6.3. Bowel Movements……………………..…………………..…..……….…..48
4.1.1.6.4. Overview through Week Four of Memantine.……………………….……..49
4.1.1.7. In-depth Overview of Study Subject M-01-B.…………………….……..…..49
4.1.1.7.1. Pain Scores……….………………………..…………………..……..……..50
4.1.1.7.2. Oxy/acet Dosage………..…………………..………………………..……..54
4.1.1.7.3. Bowel Movements……………………..…………………..…..……....…..55
4.1.2. Study Subject F-01-R.…………………….……………………………..……...55
4.1.2.1. Pre-Memantine Phase……………………..…………………..…..……..…..56
4.1.2.1.1. Pain Scores……………..…………………..………………………..……..57
4.1.2.1.2. Hydromorphone Dosage……………………….………………..…..……..61
4.1.2.1.3 Bowel Movements..……..…………………..……………………….……..62
4.1.2.1.4. Overview of Pre-Memantine Phase……..…………………..…..……..…..63
4.1.2.2. Week One of Memantine…..…………………..……………………...……..63
4.1.2.2.1. Pain Scores……….………………………..…………………..…….……..64

vii

4.1.2.2.2. Hydromorphone Dosage………..…..………..……………………………..66
4.1.2.2.3. Bowel Movements……………………..…………………..…..…………...67
4.1.2.2.4. Overview through Week One of Memantine.…………………….………..68
4.1.2.3. Week Two of Memantine…………………….………………..…..…….…..68
4.1.2.3.1. Pain Scores……….………………………..…………………..…..…...…..69
4.1.2.3.2. Hyrdromorphone Dosage………..……………..…………………………..71
4.1.2.3.3. Bowel Movements……………………..…………………..…..…..……....72
4.1.2.3.4. Overview through Week Two of Memantine.……………………….……..73
4.1.2.4. Week Three of Memantine…..…………………..…………………….……..73
4.1.2.4.1. Pain Scores……….………………………..…………………..…….……..74
4.1.2.4.2. Hydromorphone Dosage………..………………..………………….……..76
4.1.2.4.3. Bowel Movements……………………..…………………..…..…………..77
4.1.2.4.4. Overview through Week Three of Memantine.…………………….……..78
4.1.2.5. Week Four of Memantine…………………….………………..…..…….…..78
4.1.2.5.1. Pain Scores……….………………………..…………………..…..…..…..79
4.1.2.5.2. Hydromorphone Dosage………..……………..…………………….……..81
4.1.2.5.3. Bowel Movements……………………..…………………..…..…..……...82
4.1.2.5.4. Overview through Week Four of Memantine.…………………….….…..83
4.1.2.6. In-depth Overview of Study Subject M-01-B.…………………….………..83
4.1.2.6.1. Pain Scores……….………………………..…………………..…………..84
4.1.2.6.2. Hydromorphone Dosage………..……………..………………..….……..87
4.1.2.6.3. Bowel Movements……………………..…………………..…..……..…..88
Chapter 5. DISCUSSION…………………………………………………………….89
5.1. Study Patient M-01-B..……………………..…………………..……….…..…..92
5.2. Study Patient F-01-R..……………………..…………………..…..………..…..94

viii

Chapter 6. CONCLUSION………………….……………………………..………..98
Chapter 7. FUTURE DIRECTIONS………………………………………………...99
APPENDIX A: Informed Consent.……………………..…………………..……...100
APPENDIX B: Pain Diary……..….……………………..…………………..……..107
APPENDIX C: MMSE…………………..………………..…………………..…….119
APPENDIX D: Patient Study Schedule.……………………..…………………….121
REFERENCES………………………………………………………………..…….122

ix

LIST OF FIGURES

Chapter 1:
Figure 1: Effects of Namenda (memantine) on Oxycodone/acetaminophen Dosage over
Four Weeks ……………………………………………………………………. 9

Chapter 3:
Figure 2: Average Pain Scores and Bowel Movements per Week………………………19
Figure 3: Pre-memantine Phase; Daily opioid Dosage (mg)…………………………….20
Figure 4: Pre-memantine Phase; Daily opioid Dosage (mg)…………………………….21

Chapter 4.1:
Figure 5: Average Daily Pain Scores, Opioid Dosage (mg) and Bowel Movements per
Day for Week Zero…………………………………………………………….24
Figure 6: Pre-memantine phase; Daily Morning Pain Scores……………………..……..26
Figure 7: Pre-memantine phase; Daily Afternoon Pain Scores……………………...…..27
Figure 8: Pre-memantine phase; Daily Evening Pain Scores……………………...…….27
Figure 9: Pre-Memantine Phase; Average Daily Pain Scores………………………..….28
Figure 10: Pre-memantine phase; Daily Opioid Dosage (mg)…………………………..29
Figure 11: Pre-memantine phase; Daily Bowel Movements…………………………….30
Figure 12: Average Pain Scores, Opioid Dosage (mg) and Bowel Movements per
Week………………………………………………………………….……….31
Figure 13: Week One of Memantine (5 mg a.m.); Daily Pain Scores…………………..32
Figure 14: Week One of Memantine; Average Daily Pain Scores………………………33
Figure 15: Week One of Memantine; Daily Opioid Dosage (mg)……………………….33
Figure 16: Week One of Memantine; Daily Bowel Movements………………….……..34

x

Figure 17: Average Pain Scores, Average Opioid Dosage (mg) and Bowel Movements
per Week……………………………………………………………….……...35
Figure 18: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Daily Pain
Scores…………………………………………………………………………..36
Figure 19: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Average Daily Pain
Scores……………………………………………………………………….….37
Figure 20: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Daily Opioid Dosage
(mg)…………………………………………………………………………….38
Figure 21: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Daily Bowel
Movements………………………………………………………………….…39
Figure 22: Average Pain Scores, Average Opioid Dosage (mg) and Bowel Movements
per Week…………………………………………………………….……..…..40
Figure 23: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Daily Pain
Scores.................................................................................................................41
Figure 24: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Average Daily Pain
Scores…………………………………………………………………………..42
Figure 25: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Daily Opioid Dosage
(mg)…………………………………………………………………………….43
Figure 26: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Daily Bowel
Movements. ……………………………………………….………………….44
Figure 27: Average Pain Scores, Average Opioid Dosage (mg) and Bowel Movements
per Week……………………………………………………………………….44
Figure 28: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Daily Pain
Scores………………………………………………………..…………………45
Figure 29: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Average Daily Pain
Scores……………………………………………………………….………….46
Figure 30: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Daily Opioid Dosage
(mg). ……………………………………………………………………….….47
Figure 31: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Daily Bowel
Movements. ………………………………………………………….……….48

xi

Figure 32: Average Pain Scores, Average Opioid Dosage (mg) and Bowel Movements
per Week…………………………………………………………………..…...49
Figure 33: Average Morning Pain Score Per Week……………………………………..50
Figure 34: Average Afternoon Pain Score Per Week……………………………………51
Figure 35: Average Evening Pain Score Per Week…………………………….………..52
Figure 36: Average Pain Score Per Week………………………………………………..53
Figure 37: Average Opioid Dosage (mg) per Day per Week. Average weekly opioid
dosage (mg) per day for each week of the study…………………..…………..54
Figure 38: Bowel Movements per Week……………………………………...…………55
Chapter 4.2:
Figure 39: Pre-Memantine Phase; Daily Morning Pain Scores……………………….....57
Figure 40: Pre-Memantine Phase; Daily Afternoon Pain Scores………………………...58
Figure 41: Pre-Memantine Phase; Daily Evening Pain Scores…………………………..58
Figure 42: Pre-Memantine Phase; Daily Pain Scores…………………………...……….59
Figure 43: Pre-Memantine Phase; Average Daily Pain Scores…………………...……..60
Figure 44: Pre-Memantine Phase; Daily Opioid Dosage (mg)…………………………..61
Figure 45: Pre-Memantine Phase; Daily Bowel Movements. ……………………….…62
Figure 46: Average Pain Scores, Average Opioid Dosage (mg) and Bowel Movements
per Week…………………………………………………………………….…63
Figure 47: Week One of Memantine (5 mg a.m.); Daily Pain Scores…………….…….64
Figure 48: Week One of Memantine (5 mg a.m.); Average Daily Pain Scores…..……..65
Figure 49: Week One of Memantine (5 mg a.m.); Daily Opioid Dosage (mg)………….66
Figure 50: Week One of Memantine (5 mg a.m.); Daily Bowel Movements……….….67
Figure 51: Average Pain Scores, Average Opioid Dosage (mg) and Bowel Movements
per Week……………………………………………………………………….68
Figure 52: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Daily Pain Scores……69

xii

Figure 53: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Average Daily Pain
Scores…………………………………………………………………………..70
Figure 54: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Daily Opioid Dosage
(mg)………………………………………………………………………….…71
Figure 55: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Daily Bowel
Movements. …………………………………………………….…………….72
Figure 56: Average Pain Scores, Average Opioid Dosage (mg) and Bowel Movements
per Week……………………………………………………………….………73
Figure 57: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Daily Pain
Scores………………………………………………………………….……….74
Figure 58: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Average Daily Pain
Scores……………………………………………………………………….….75
Figure 59: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Daily Opioid Dosage
(mg)…………………………………………………………………………….76
Figure 60: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Daily Bowel
Movements……………………………………………………………………..77
Figure 61: Average Pain Scores, Average Opioid Dosage (mg) and Bowel Movements
per Week……………………………………………………………………….78
Figure 62: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Daily Pain
Scores……….………………………………………………………………….79
Figure 63: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Average Daily Pain
Scores…………………………………………………………………………..80
Figure 64: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Daily Opioid Dosage
(mg). ……………………………………………………………………….….81
Figure 65: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Daily Bowel
Movements. ………………………………………………………..………….82
Figure 66: Average Pain Scores, Average Opioid Dosage (mg) and Bowel Movements
per Week…………………………………………………………………….…83
Figure 67: Average Morning Pain Score Per Week………………………………….….84
Figure 68: Average Afternoon Pain Score Per Week………………………..……….….85

xiii

Figure 69: Average Evening Pain Score Per Week………………………….………….85
Figure 70: Average Pain Score Per Week…………………………………………..…..86
Figure 71: Average Opioid Dosage (mg) per Day per Week…………………..…….…87
Figure 72: Bowel Movements per Week…………………………………………….….88

xiv

ACKNOWLEGDMENTS

I would like to thank all of the patients that were involved in some way in this
study. I would also like to thank Dr. Frederick Goldstein, my thesis advisor, Dr. Heather
Montie, thesis committee member, Dr. Katherine Galluzzi, thesis committee member, Dr.
Marcus Bell, Director, Graduate Program in Biomedical Sciences, Philadelphia College
of Osteopathic Medicine and the Center for Chronic Disorders of Aging (CCDA) at
PCOM.

1

Chapter 1
INTRODUCTION

Approximately 20 percent of adults live with moderate to severe chronic pain that
lasts for six months or longer [15]. Opioids may be considered to be the first drug of
choice to combat severe chronic pain; over the past decade there has been an exponential
increase in opioid prescriptions in the United States, Australia, and Europe [15]. Typical
opioids available to treat chronic pain include morphine, codeine, oxycodone, fentanyl,
and buprenorphine that are administered in multiple forms, e.g., tablet, skin patch,
sublingual liquid. For individuals with persistent severe pain (―high impact pain‖), high
levels of opioid dosage result in improved analgesia but also increase the frequency
and/or intensity of adverse effects; these reactions include sedation, impaired cognitive
function, depression, constipation, and bladder dysfunction [15]. Endocrine dysfunction
can develop such as hypogonadism/hypotestosteronism caused by central depression of
hypothalamic secretion [9]. Furthermore, despite an increase in dosage, it is common for
opioids to become ineffective over time due to tolerance, which, consequently, increases
adverse effects. There is a risk that the patient may abuse, misuse or divert these
medications. According to the American Society of Addiction Medicine, ―Of the 21.5
million Americans 12 or older that had a substance use disorder in 2014, 1.9 million had
a substance use disorder involving prescription pain relievers and 586,000 had a
substance use disorder involving heroin‖ [1]. Patients develop tolerance to many
pharmacological properties such as sedation, respiratory depression and nausea but not to
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gastrointestinal hypomotility. With increased opioid dosage, this adverse effect becomes
a major problem in the life of a chronic pain patient which can decrease the quality of
living.
Pain can be described as a dynamic phenomenon, influenced by various
mechanisms of excitatory and inhibitory control. Gender can factor into the amount of
pain a patient experiences, due to varied levels of hormones in each system that are
produced by the ovaries and testes. The different amount of hormones produced by each
sex may have a direct impact on the perception of pain. Estradiol which is produced by
the testes and more so in ovaries, can potentiate glutamate binding to NMDAr [18].
A retrospective cohort study was performed to determine if a gender difference
exists in the incidence of severe postoperative pain episodes. Pain scores were collected
from various types of non-ambulatory surgical procedures (e.g. coronary artery bypass
graft, heart valve procedures, and laminectomy) using the Numeric Rating Scale (NRS),
which is an 11 point scale (0-10) with 0 being no pain at all and 10 being the worst pain
ever experienced. In addition, the incidence of severe pain events was determined by
employing a SPE (Sudden Painful Events) scale; which is how many episodes of suddenonset pain were experienced post-surgery. Evaluation of 333,000 pain scores between
males and females, in similar procedural categorizations, resulted in a statistical
difference. At post-operative day (POD) 1, the female averaged pain score was 4.20 with
males at 3.98 (mean difference 0.22, 99% Cl 0.16-0.28, p<0.0001). At POD 5, the female
average pain score was 4.11, and male average of 3.74 (mean difference 0.36, 99% Cl
0.33-0.40, p<0.0001). With these data, it was concluded that, on average, females report
higher numeric pain intensity ratings within a clinical environment and that they
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experience a greater incidence of SPEs on POD 1. Also, through the NRS pain scores,
females had increasing pain through POD 5, which shows that males had a quicker
decrease in pain than females [24].
A survey was performed to determine differences between females and males
during a painful stimulus by studying the relationship between gonadal hormones and the
central nervous system. When considering the epidemiology of sex differences in pain,
researchers found that females tend to report more severe pain and longer lasting pain
than their male counterparts with similar disease processes such as irritable bowel
syndrome, chronic pelvic pain and interstitial cystitis. Females also have a more frequent
prevalence of pain when the pain is related to musculoskeletal, visceral origin or
autoimmune diseases like lupus and rheumatoid arthritis. Also, females are more likely to
visit a physician when experiencing pain and use significantly more pain-relieving
medications, even when the frequency and severity of pain was equated for the sexes. To
explain this finding, there was a consideration of gonadal steroid hormones produced by
the ovaries and testes. The testes mainly produce androgens, testosterone, and
dihydrotestosterone, whereas, the ovaries mainly produce estrogens and progestin. The
precise roles of these biological substances in relation to pain are not yet well understood.
Effects on pain and analgesia were first thought to be caused by release of gonadal
hormones and are possibly due to de novo hormone synthesis in the affected tissues. The
hypothesis that gonadal hormones can affect sensitivity to pain when an organism is
developing and throughout adulthood has also been tested in this research by examining
the endogenous opioid neurotransmitters and μ opioid receptors. Females and males
differ in their concentration of μ opioid receptors, which may be due to age and the
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amount of circulating gonadal steroids [18]. According to the researchers, in various
human experiments, females are generally found to have a greater amount of μ opioid
receptors in the periaqueductal gray (PAG), including descending projections to the
rostral ventral medulla (RVM) and dorsal horn of the spinal cord, when measured
with positron emission tomography. Researchers used the individual gender role
expectations of pain (GREP) on experimental pain report and VAS to rate pain intensity.
Males showed significantly higher pain endurance than females with similar disease, but
females indicated a greater willingness to report pain. These investigators performed
another study to assess the difference between genders regarding response to
interdisciplinary chronic pain management. Females were found to have a greater benefit
from pain management than males, although the investigators did not discuss why this
occurred. Interdisciplinary chronic pain management is a series of therapies relating to
pain and distress at three time points (immediately prior, on completion, and three
months following intervention). This includes PT/OT, psychology, pharmacology, ect.
Also reported was greater morphine analgesia in men than women, and women needed
about 30% more morphine to have the same level of analgesia as men after surgical
removal of the third molar tooth [18].
In a study comparing effects of patient-controlled analgesia (PCA) with morphine
between women and men from trauma-related pain (not specified), as the PCA duration
was increased, there was also a positive correlation in the morphine effect between the
sexes, the morphine effect also increased (n=11, 95% c.i. 0.01-0.69, p=0.047). When
considering μ opioid receptors in experimental pain studies, women had a larger decrease
of painful stimulus by sensory neurons while taking opioids when compared to men, as
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seen from performing a sensitivity analysis (n=11, effect size=0.36, 95% c.i. 0.17-0.56,
p=0.003). Although there are no pharmacokinetic gender differences, morphine was more
effective in women at lower dosages, but had a slower onset of action. Researchers are
still uncertain about the reasoning behind the latter effect, but it may be explained by
slower progression though the blood-brain barrier or to the sex differences in receptor ligand kinetics. Although there is greater morphine effectiveness in women once the
relatively delayed effect is appreciated, men exhibit an analgesic greater effect directly
after injection [17].
To improve safety, efficacy and reduce the potential for addiction and abuse,
chronic pain can be treated through a variety of different categories of non-opioid
medications instead of, or in conjunction with, opioids. Medications that can be used to
complement opioids include acetaminophen, non-steroidal anti-inflammatory drugs
(NSAIDs), antidepressants, anticonvulsants, and benzodiazepines. The most common
non-opioid medications used to treat chronic pain that can result from trauma, arthritis,
surgery, or cancer are acetaminophen and NSAIDs; they are effective when taken alone
or in combination with opioids. Acetaminophen is a non-salicylate that has analgesic and
antipyretic effects similar to aspirin. Although acetaminophen does not irritate the gastric
mucosa, use of this drug must be monitored in patients who consume alcohol daily and/or
have underlying liver disease due to the fact that they can develop acetaminopheninduced hepatotoxicity. The disadvantage of NSAIDs is that they have a ceiling effect,
i.e., once a therapeutic ceiling level has been established, any further increases in dosage
will increase side effects without additional analgesia. Physicians must be cautious when
prescribing NSAIDs in conjunction with opioid therapy, especially in elderly patients
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with certain medical co-morbidities as they can cause gastrointestinal (GI) bleeding,
impairment in renal function and, most importantly, have been linkded to cardiovascular
events. The most common side effects are GI consisting of anorexia, dyspepsia, nausea,
abdominal pain and diarrhea. Tricyclic antidepressants (TCAs) when administered with
opioids, improve analgesia. Patients who received opioid medications with intramuscular
amitriptyline after a cholecystectomy [6] or cesarean section [25] showed a reduction in
the amount of opioid needed to improve analgesia. TCA analgesic effects are shown to
work in as little as 24 hours of use, while antidepressant actions can take up to a week or
more to appear [11]. It is believed that the mechanisms of TCAs are related to blocking
serotonin and norepinephrine reuptake, and stabilizing nerve membranes [11].
Anticonvulsants such as gabapentin and pregabalin can be used successfully when
treating pain if opioid medication therapy is not effective, e.g., in diabetic neuropathy or
trigeminal neuralgia. This is due the main actions of anticonvulsants that decrease
voltage-gated calcium or sodium channels, and improved performance of the gammaaminobutyric acid (GABA) inhibitory system [11].
Patients in chronic pain who are on opioids can experience anxiety and mood
disorders. Adding benzodiazepines in this situation can be useful; however, it can
increase the chance of respiratory depression, and also misuse or addiction [11].
A recent study was conducted in patients with post-operative stump pain after
major lower limb amputation. This research involved 198 patients over a four-year
period; 102 received a perineural catheter and were compared to 96 patients who did not
receive the perineural catheter. The catheter was used to bathe the nerve endings with
analgesic medications. By multiple regression analyses, perineural catheter use was
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shown to lower cumulative post-op opioid consumption over the first 72 hours.
Researchers compared the amount of morphine needed between the two groups in the
first 72 hours post-op, along with the post-operative pain intensity within the first 24
hours. Analgesic medications were converted to morphine equivalents and patients who
received a perineural catheter required less cumulative post-operative opioid medication
over the first 72 hours (catheter 81.23 ± 90.77 mL/hr vs. non-catheter 134.51 ± 145.49
mL/hr, p = 0.03), leading to a lower adverse effect rate of sedation and nausea, leading to
a greater quality of life for the patients [2].
Other effective adjuncts to opioid therapy for the treatment of chronic pain are Nmethyl-D-aspartate receptor (NMDAr) antagonists. Ketamine is such an agent but has
serious adverse drug reactions including dysphoria and hallucinations which limit clinical
use (Parsons et al. 2013). Memantine can be a useful alternative to ketamine because the
former is an NMDAr antagonist that has a pivotal action in the hippocampus of the brain.
Glutamate activates the NMDAr, causing calcium (Ca 2+) ions to move into the postsynaptic neuron, triggering a signal cascade leading to long-term potentiation (LTP),
producing a greater order of learning and memory [19]. NMDA can impair LTP in the
hippocampus, but the action of memantine can prevent that effect [19]. This led to the
theory that memantine could be used as a possible treatment for neuropathic pain due to
an effect on the NMDA receptor, since the neurotransmitter glutamate is associated with
neuropathic pain.
Glutamate acting on an NMDA receptor causes the postsynaptic cell to become
more sensitive to input signals. Memantine blocks excessive NMDA receptor activity
without disturbing normal activity. The properties of memantine that allow such an effect
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are that it is a noncompetitive, low-affinity, open-channel blocker. When the NMDA
receptor-associated ion channel is excessively open, memantine acts as a fast-shut off but
will not accumulate in the channel, allowing for normal synaptic transmission [20].
Memantine is highly absorbed after oral administration. Peak concentrations can
be reached within 3-7 hours after administration and the intake of food does not affect the
absorption of memantine. Memantine has a half-life of 60-80 hours and is mostly
excreted by tubular secretion [4]. The majority of the administered memantine (57-82%)
is excreted unchanged in the urine and the remaining percentage is converted primarily
into three polar metabolites which possess minimal NMDA receptor antagonist activity
[22].
Minimal inhibition of CYP450 enzymes including CYP1A2, CYP2A6, CYP2C9,
CYP2D6, CYP2E1, and CYP3A4 (most involved in biotransformation of opioids) have
been observed in in vitro studies with memantine. Due to this low activity here,
pharmacokinetic interactions with other medications metabolized by these enzymes are
not likely [14].
An unpublished pilot investigational study on three geriatric patients taking a
daily regimen of oxycodone/acetaminophen combinations for non-specific chronic pain
for more than two months revealed that adding memantine orally for 28 days, following
the approved FDA regimen for Alzheimer‘s Disease, allowed patients to reduce the
amount of their pain medication [5] (Figure 1).
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Figure 1. Effects of Namenda (memantine) on Oxycodone/acetaminophen
Dosage over Four Weeks

In a comprehensive randomized clinical trial, memantine was administered to
improve post-operative pain from a breast cancer surgical treatment. This study was
performed as a pilot clinical trial. Half of the patients received memantine both before
and after surgery at an increasing dosage following the FDA approved schedule for
Alzheimer‘s Disease (i.e., 5 mg a.m. on Week One, 5 mg a.m. and p.m. on Week Two,
10 mg a.m. and 5 mg p.m. on Week Three, 10 mg a.m. and 10 mg p.m. on Week 4),
while the other group received a placebo (lactose) in the same time frame as the
experimental group. At three months post-surgery, pain scores (0-10) were obtained and
evaluated between control and memantine groups. Patients who received memantine
reported less pain intensity, and less rescue analgesic (acetaminophen, NSAIDs, tramadol
and morphine) dosage when matched with patients receiving only placebo. Pain scores
were significantly lower in the memantine group (placebo: 1.3 ± 1.8; memantine: 0.2 ±
0.4, p= 0.017). It was concluded that patients who underwent mastectomy had less

10

neuropathic pain and an improved state of well-being when memantine was added both
before and after surgery compared to control [16].
This correlates with an earlier study performed where six patients were treated
with memantine for eight weeks after they had developed complex regional pain
syndrome in the upper extremity following traumatic injury. In this investigation,
memantine was given orally starting with 5 mg per day and increasing doses 5 mg every
second day until a final target dose of 30 mg/d was achieved; it was also administered
twice a day once the target dose was reached (15 mg/morning and 15 mg/evening). After
six months post-treatment with memantine, all patients showed a significant decrease in
pain scores dropping from an average score of 9.78 to 1.17 (p = 0.0001) [23].
In 2010, Gustin et al. performed a study in patients presenting with regional pain
syndrome. They were given memantine as an adjunct to morphine to try to reduce their
VAS pain score. Memantine was titrated from 5 to 40 mg over 15 days and maintained at
40 mg for another 34 days in order to minimize side effects due to this combination
therapy. Patients who received memantine showed a significant difference in their VAS
pain score at the affected limb by completing a numeric pain intensity scale (0—no pain,
10—maximum pain) after active clenching of the hand (five times) and during rest (5.47
to 1.40, p < 0.001). This indicates that using memantine as an adjunct to morphine
improved analgesia. The mood of patients receiving memantine was also shown to
significantly improve when compared to those who received a placebo (0.90 to 5.08, p <
0.001). This was measured using the Center for Epidemiologic Studies Depression Scale,
which is a numerical questionnaire and can be related to the reduction of pain [8].
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A more recent similar study involved adding memantine to methadone as an
adjunct. Patients were chosen according to the Diagnostic and Statistical Manual of
Mental Disorders, fourth edition (DSM-IV) criteria for opioid-dependence. They were
divided into randomized groups where one received a placebo plus methadone while the
other group was administered memantine (5 mg memantine sustained-release capsule) for
12 weeks with methadone. Results showed that the dosage of methadone required by
patients also receiving memantine was significantly lower than the placebo group
(p = 0.034); it decreased in patients by 0.950 mg over the 12-week study period [12].
Results of these studies show that using memantine as an adjunct lowered the
amount of pain, improved mood and decreased opioid dosage.
In this pilot study, memantine was added to patients taking immediate-release
opioids, oxycodone, oxycodone/acetaminophen or hydromorphone, for at least two
months; both office-based and nursing home patients were recruited. As a result of
decreased opioid use, patients were hypothesized to experience fewer and/or less intense
adverse effects; this outcome would be expected to improve their quality of life.
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Chapter 2
METHODS

This pilot study was conducted to determine whether the addition of memantine to
an established opioid analgesic regimen had measurable effects on analgesia, need for
rescue pain medications or laxation. Objectives were to determine any reduction of daily
dose of opioid medication, pain scores and constipation. This adjunctive agent was added
to patients taking a combined oxycodone/acetaminophen formulation or hydromorphone
for a minimum of two months.
Approval to conduct this research was obtained from the Institutional Review
Board (IRB) at Philadelphia College of Osteopathic Medicine (PCOM) for two nursing
homes located in Philadelphia (Bala Nursing and Rehabilitation Center [B]; St. Ignatius
Nursing Home [S] on August 10, 2016. Additional IRB approval was obtained to recruit
patients from the PCOM office-based practices of Katherine Galluzzi, DO, and Larry
Finkelstein, DO on January 8, 2017. This study was an AB Design study, in which the
patient initially did not receive treatment (A) and then was given the study drug (B).
Inclusion criteria for this study were patients who are at least 18 years of age or older,
taking opioids daily for two months for chronic pain, and able to sign the consent form.
Patients were not able to participate in this study if they were taking certain
antidepressants (TCAs and SNRIs) for less than 6 weeks, antipsychotics, or Alzheimer‘s
Disease medication. Other exclusion criteria included non-English speaking patients or
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those with, gastric motility problems, pregnancy, or planned pregnancy during the 6
weeks of participation in this study.
A screening process was performed by the attending physician and student
investigators. Student investigators performed a Mini Mental State Exam (MMSE)
(Appendix C) on patients that were reported to be on short-acting opioid therapy in order
to gauge their cognitive function. The physician then contacted patients who were
cognitively capable of participating to ask them to volunteer to be potential study
subjects. After consulting with the potential study subject, the physician asked the patient
to explain this study back to them in order to assure complete understanding of what was
expected. Patients that were asked to volunteer for this study were then given a consent
form (Appendix A) in which they could review with their families and significant others.
After one week, patients were asked for their decision and if they had any questions that
may have arisen; these were answered by their physician. To maintain confidentiality,
signed consent form documents and pain diary documents were kept in a locked file
cabinet, as required by the IRB. Patients who decided not to be part of the study or
decided to stop in the middle of this investigation were assured that they would continue
to receive the same care from the staff and their physician.
Since this investigation was a pilot study with a small sample size and
administration of memantine was off-label, it was not randomized, and a placebo was not
used. Patients were allowed to use as much of their opioid daily as needed. Due to the
fact that pain is variable from person to person, the amount of pain medication that each
patient would require differs, therefore, each study subject served as his/her own control.
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Memantine, provided from Verree Pharmacy located in Northeast Philadelphia,
was given daily for 28 days in a row after a two-week pre-memantine phase to determine
if the study patient could comply with all study requirements and to also obtain a baseline
for the amount of opioid patients were taking, as well as their baseline pain score (Day 1Day 14). A baseline was important in order to identify existing patterns of the opioid use
by the patient and allow for a more accurate interpretation of the results. Memantine was
delivered in a kit prepared by Verree Pharmacy with five bottles in each to be
administered to the patients by nursing staff at the nursing facility. Office out-patient
memantine kits were delivered to PCOM and each weekly corresponding bottle was
given to the patient each week when they came into the office. All bottles were labeled
with the corresponding week, and a number, Week 3: Bottle 1: 7 tablets of 5 mg each,
Week 4: Bottle 2: 14 tablets of 5mg each, Week 5: Bottle 3: 7 tablets of 5 mg each Week
5: Bottle 4: 7 tablets of 10 mg each, Week 6: Bottle 5: 14 tablets of 10 mg each. Each
bottle label also contained the date; subject ID, memantine dose per day, instructions,
week number and physician name. Each was placed in a prescription bag with a unique
kit number, with a label that included the number followed by Memantine-Opioid
Clinical Investigation for research study use only.

The first part of this study was the pre-memantine phase, in which memantine was
not administered and patients were asked a series of questions in a weekly pain diary
(Appendix B). The questions were, 1.) How much of your pain medicine you are taking
every day? 2.) How much pain you are having every day? 3.) How many bowel
movements you are having every day? Pain was assessed by using an 11 point scale, zero
being no pain at all and 10 being the worst possible pain. During the two-week pre-
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memantine phase student investigators came in for a brief visit every day to learn how the
patient was feeling. The patient then had a short discussion with their doctor regarding
the desire to continue with this study. If the patient wanted to remain in the study, part
two began immediately. During this phase, the patient took memantine for 28 days as
follows, Week 3 – 5 mg in the morning for the first 7 days, Week 4 – 5 mg in the
morning and 5 mg in the evening for the next 7 days, Week 5 – 10 mg in the morning and
5 mg in the evening for the next 7 days, Week 6 –10 mg in the morning and 10 mg in the
evening for the next 7 days (Appendix D). This titrated dosage regimen is exactly the
dosage regimen approved by the FDA for treatment of Alzheimer‘s Disease. It was
important to conduct a titration scale for this medication because patient comfort was of
utmost importance. The risk of adverse effects from this medication is increased if not
titrated properly. Administering memantine through this process to reach a target dose
allowed physicians and nursing staff to monitor any adverse effects that may occur while
taking the medication. Due to the fact that this was an off-label use of memantine, after
the four week administration period, the patients did not receive continual administration
of this medicine through this study. The cost of memantine for a four-week supply is
$50.00 which was covered by the PCOM Center for Chronic Diseases of Aging for the
duration of the investigation. If the patient wanted to continue to use memantine off-label
after the study was completed, a prescription had to be written by the primary physician
of the patient.
For patients that resided in a nursing home, the first visit was a normal one where
there was an initial identification of them for the study and discussion of the study; then
the consent form was given. The next visit was for pre-study evaluation; if inclusion and
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exclusion criteria were met, the patient was asked to sign the consent form, and Weeks
one and two pain diary sheets were started. During the first week, student investigators
visited the study subject in the afternoon and evening to ensure that the patient was
compliant with the procedure (Day 1 –Day 7). The second week followed the schedule of
the first week, in which the student investigators visited the patients to ensure they were
remaining compliant with their daily pain diary logs (Day 8- Day 15). On Day 15, if the
patient remained compliant, the treatment phase was started where memantine was
administered and the pain diary sheets for Weeks three and four were started. Student
investigators continued to meet with patients at the same time in the afternoon and
evening (Day 16- Day 28). On Day 29 the treatment phase continued and diary sheets for
Weeks five and six were started and student investigators continued to visit in the
afternoon and evening (Day 29 – Day 42). Day 43 was the last visit and the end of
participation for patients in this study. Student investigators visited the patient in the
afternoon and evening to collect final data.
The study subject was visited two times per day by student investigators, once at
noon and once in the evening. There were a total of 84 visits over the six week study
period and each visit took approximately three minutes, leading to a total of 4.2 hours of
time spent with each study subject. At the nursing home, student investigators were
granted access to their Millennium Database to gain access to patient records for data
collection. Data was collected from the morning by the patient directly writing in the pain
diary. Mid-day and evening data were collected via one-on-one interviews between
patients and Student Investigators.
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PCOM office out-patient data were collected on a weekly basis; however, the pain
dairy information remained the same. The first visit was a normal visit where there was
an initial identification for the study, discussion of the study and the consent form was
given. The next visit, a week later, was the pre-study evaluation visit, where, if inclusion
and exclusion criteria are met, the patient was asked to sign the consent form and week
one pain diary was started. The patients came into the office each week of the study to
hand in their pain diary for the previous week and start the pain diary for the next week.
After the two week pre-memantine phase was completed to a satisfactory level,
memantine was distributed to the patient in weekly bottles. The patient returned to the
office each week to submit pain dairy data and to collect the next weekly dose of
memantine until completion of the study. After the six-week study, all the data collected
were combined.
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Chapter 3

RESULTS

3.1. PART A

Patients who volunteered were given designated codes to de-identify them except
to the investigators. Seven patients were involved, four from one of the nursing homes
(B) and three office out-patients. Patients from the nursing home were designated as M
[Male]-01-B, M-02-B, M-03-B and M-04-B. Office out-patients were designated as M01-R, M-02-R and F [Female]-01-R. However, three nursing home patients, M-02-B, M03-B and M-04-B, did not continue the study after the pre-memantine phase and did not
receive any memantine.
Patients followed by this Student Investigator were M-01-B M-02-B, M-03-B, M04-B and F-01-R; those followed by Student Investigator, Lisa English, were M-01-R and
M-02-R.

3.1.1. Study Subject M-02-B
He was an 81 year-old male with chronic hand and leg pain due to osteopenia. He
received oxycodone, 5 mg + acetaminophen (oxy/acet) orally per os (p.o.), as needed pro
re nata (prn), every six hours quaque sex hora (q6). This patient was removed from the
study during the second week of the pre-memantine phase because he was not taking
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enough of the generic combination of oxycodone, 5 mg + acetaminophen (oxy/acet)
(Figure 2) and it would have been difficult to observe a reduction in his opioid intake
throughout the study.

Pain Score, Opioid Dosage (mg), Bowel
Movements

Average Pain Scores, Opioid Dosage (mg) and
Bowel Movements per Week
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Figure 2: Average Pain Scores and Bowel Movements per Week. Average weekly
pain scores and bowel movements per day during the Pre-Memantine Phase of M-02-B.

Once this patient was removed from the study, he started physical therapy and
thought he would be using more oxy/acet. Extensive monitoring was initiated to observe
if he could be reintroduced into the study. Unfortunately, he passed away from a heart
condition four days before starting memantine.
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3.1.2. Study Subject M-03-B
He was a 71 year-old male with chronic left side hip and leg pain due to an
unspecified bone disorder and a fractured left femur. He received oxycodone 10 mg p.o.
prn, every four hours quaque quarta hora (q4). This patient was able to complete the
full-two week pre-memantine phase but when the memantine phase was to start, he was
admitted to the hospital to undergo left hip surgery. Due to this unexpected event, the
memantine phase was halted, and a decision was made remove the patient from the study.
Another factor in his removal was a drop in pain scores from week one to week two
(Figure 3). Due to this reduction without any intervention with memantine it would have
been difficult to determine if the memantine, caused the decrease or it was due to a
different cause.
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Figure 3: Pre-Memantine Phase; Daily opioid Dosage (mg). Daily opioid dosage (mg)
for the length of time M-03-B was included in the study.
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3.1.3. Study Subject M-04-B

He was a 65 year old male with chronic back and leg pain who was taking
oxy/acet 5-325 p.o. prn q6. This patient was taken out of the study after the first week of
the Pre-Memantine Phase because he was not able to keep an accurate pain diary (Figure
4). Also, he underwent surgery for a new pacemaker during the beginning of the second
week of the Pre-Memantine Phase. Another factor in his elimination was his daily inquiry
as to when he would be receiving the memantine even though the two week PreMemantine Phase was explained to him every time. This was perceived as though the
patient did not fully understand the study.
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Figure 4: Pre-Memantine Phase; Daily opioid Dosage (mg). Daily opioid dosage (mg)
for the length of time M-04-B was included in the study.

These instances of nursing home patients indicated that their health instability
made it difficult to collect and analyze accurate data; the decision was altered to recruit
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office out-patients who would likely be more compliant, which would permit collection
of more accurate data.
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Chapter 4
RESULTS

4.1 PART B

4.1.1. Study Subject M-01-B

The first patient receiving memantine in this study, was a good candidate for this
study because and was taking oxy/acet; this was administered via percutaneous
endoscopic gastrostomy (PEG) tube, prn q4 for a pressure ulcer on his left heel, phantom
pain from an amputated right fifth digit phalanx, and chest pain from the PEG tube.
However, due to unforeseen circumstances, data accumulated from M-01-B are not as
accurate as possible; however, they served as preliminary information to determine if a
trend could be observed.
The first circumstance was that the patient did not understand his oxy/acet
prescription was prn and that he had to ask for it when needed. In the beginning, he
assumed his opioid was given to him regularly. During the first week of the prememantine phase he did not receive any for four days straight due to this
misunderstanding (Figure 5). After explaining what ‗as needed‘ meant, the number of
oxy/acet he received increased. Due to his confusion, it was decided to extend the prememantine phase an additional week to obtain better data; the first week was renamed
Week 0. This increased the study period from six to seven weeks in total.
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4.1.1.1. Overview of Week Zero:

Pain Score, Opioid Dosage (mg), Bowel
Movements

Average Pain Scores, Opioid Dosage (mg) and
Bowel Movements for Week Zero
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Figure 5. Average Daily Pain Scores, Opioid Dosage (mg) and Bowel Movements per
Day for Week Zero. Average daily pain scores, opioid dosage (mg) and bowel
movements for each day of week zero.

The second circumstance was a staff participation issue in the nursing home.
There were times where oxy/acet given to the patient, but it was not recorded by the staff
on their electronic medical records. On multiple occasions, the patient knew he had
received oxy/acet even though it was not on the Medication Administration Record
(MAR). When staff were questioned, it was confirmed that he was given oxy/acet but
they failed to record the dosage in the MAR. Due to this circumstance the number of
oxy/acet tablets the patient actually received may not be accurate; thus these data are
likely skewed. The third circumstance happened when the patient used the emergency
call button in his room to alert the staff that he needed an oxy/acet due to significant pain.
However, the patient described that it took anywhere between one and two hours until
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someone came to his room to give him an oxy/acet. It got to the point where the patient
gave up trying to get the attention of the staff and just dealt with the pain. This further
skews the data obtained from this patient because the actual amount of oxy/acet he
needed was not reflected in the amount he was given. These issues were brought to the
attention of the Director of Nursing which seemed to resolve the problems for a few days,
but eventually they returned.
There were also problems with the labels on the memantine bottles. Week 3
should have been labeled 10 mg in the morning and 5 mg in the evening. However,
unfortunately, the dosages were switched which resulted in the patient missing out on a
10 mg dose on the first day of Week 3. Also for an unexplained reason, on the last day of
Week 3, the memantine medication was discontinued which resulted in another missed
10 mg dose on the first day of Week 4.
Since there were many inconsistencies with this patient and his treatment plan, the
data collected from him cannot be used in the final overall results for this study.
However, they can be employed as preliminary results to observe if there were any
changes.

4.1.1.2. Pre-Memantine Phase

Daily morning pain scores stayed fairly constant over the two week prememantine phase (Figure 6).
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4.1.1.2.1. Pain Scores

Daily Morning Pain Scores
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Figure 6: Pre-memantine phase; Daily Morning Pain Scores. Daily morning pain
scores over the two week pre-memantine phase.

However, afternoon (Figure 7) and evening (Figure 8) reports dropped slightly
during the pre-memantine phase.

27

Daily Afternoon Pain Scores
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Figure 7: Pre-memantine phase; Daily Afternoon Pain Scores. Daily afternoon pain
scores over the two week pre-memantine phase.

Daily Evening Pain Scores
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Figure 8: Pre-memantine phase; Daily Evening Pain Scores. Daily evening pain
scores over the two week pre-memantine phase.
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In the first two weeks there was a slight decrease in average daily pain scores
from week one to week two (Figure 9).
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Figure 9: Pre-Memantine Phase; Average Daily Pain Scores. Averages of Morning,
Afternoon and Evening pain scores for each day over the two week pre-memantine phase.

There was also a decrease in the average opioid dosage (mg) from week one to
week two (Figure 10) and cannot be used to explain the decrease in average daily pain
scores for this week.
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4.1.1.2.2. Oxy/acet Dosage

Daily Opioid Dosage (mg)

Pre-Memantine Phase; Daily Opioid
Dosage (mg)
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Figure 10: Pre-memantine phase; Daily Opioid Dosage (mg). Daily opioid dosages
(mg) for each day over the two week pre-memantine phase. ? = discrepancies.

There was also a slight decrease in bowel movements from week one to week two
(Figure 11).
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4.1.1.2.3 Bowel Movements
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Figure 11: Pre-memantine phase; Daily Bowel Movements. Daily bowel movements
for each day over the two week pre-memantine phase.
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4.1.1.2.4. Overview of Pre-Memantine Phase
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Figure 12. Average Pain Scores, Opioid Dosage (mg) and Bowel Movements per
Week. Average weekly pain scores, opioid dosage (mg) and bowel movements for the
first two weeks of the study.
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4.1.1.3. Week One of Memantine

4.1.1.3.1. Pain Scores:

Week One of Memantine (5 mg a.m.);
Daily Pain Scores
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Figure 13: Week One of Memantine (5 mg a.m.); Daily Pain Scores. Morning,
afternoon and evening pain scores for each day over the first week of memantine.
(*Patient spent 6+ hours in the hospital due to PEG tube needing to be replaced).

Average daily pain scores for week one (Figure 14) remained fairly constant, as
did opioid dosage (mg) (Figure 15).
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Average Daily Pain Scores
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Figure 14: Week One of Memantine; Average Daily Pain Scores. Averages of
morning, afternoon and evening pain scores for each day over the first week of
memantine.

4.1.1.3.2. Oxy/acet Dosage
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Figure 15: Week One of Memantine; Daily Opioid Dosage (mg). Daily opioid dosages
(mg) for each day of the first week of memantine.
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Bowel movements for week one exhibited no remarkable characteristics (Figure
16) but decreased slightly from the pre-memantine phase (Figure 17).

4.1.1.3.3. Bowel Movements:
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Figure 16: Week One of Memantine; Daily Bowel Movements. Daily bowel
movements for each day of the first week of memantine.
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4.1.1.3.4. Overview through Week One of Memantine
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Figure 17. Average Pain Scores, Average Opioid Dosage (mg) and Bowel
Movements per Week. Average weekly Pain Scores, Opioid Dosage (mg) and Bowel
Movements for the first three weeks of the study. Arrow indicates when memantine was
first introduced.

4.1.1.4. Week Two of Memantine

Week two of memantine (5 mg a.m.. & 5 mg p.m.) followed the same trend of
week one of memantine with the afternoon pain scores being generally lower than the
morning and evening pain scores (Figure 18).
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4.1.1.4.1. Pain Scores
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Figure 18: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Daily Pain Scores.
Morning, afternoon and evening pain scores for each day over the second week of
memantine.

The average pain score during each day of Week Two of memantine did drop
from the beginning to the end of the week (Figure 19).
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Average Daily Pain Scores

Week Two of Memantine (5 mg a.m. &
5 mg p.m.); Average Daily Pain Scores
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Figure 19: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Average Daily Pain
Scores. Averages of morning, afternoon and evening pain scores for each day over the
second week of memantine.

Daily opioid dosages (mg) for the second week of memantine were relatively
constant with 5 or 10 mg throughout the week (Figure 20).
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4.1.1.4.2. Oxy/acet Dosage
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Figure 20: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Daily Opioid Dosage
(mg). Daily opioid dosages (mg) for each day of the second week of memantine. ? =
discrepancy.

Bowel movements for this week exhibited no unique characteristics (Figure 21)
but increased slightly from the previous week (Figure 22).
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4.1.1.4.3. Bowel Movements
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Figure 21: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Daily Bowel
Movements. Daily bowel movements for each day of the second week of memantine.
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4.1.1.4.4. Overview through Week Two of Memantine
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Figure 22. Average Pain Scores, Average Opioid Dosage (mg) and Bowel
Movements per Week. Average weekly pain scores, opioid dosage (mg) and bowel
movements for the first four weeks of the study. arrow indicates when memantine was
first introduced.

4.1.1.5. Week Three of Memantine

The trend followed into the third week of memantine (10 mg a.m. & 5 mg p.m.)
(Figure 23).
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4.1.1.5.1. Pain Scores
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Figure 23: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Daily Pain Scores.
Morning, afternoon and evening pain scores for each day over the third week of
memantine. (*) = missed memantine dose.

Afternoon pain scores were generally lower than both morning and evening pain
scores but increased in the weekend. The average daily pain score for the third week
stayed relatively constant, but were lower than that in week two (Figure 24).
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Average Daily Pain Scores
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Figure 24: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Average Daily
Pain Scores. Averages of morning, afternoon and evening pain scores for each day over
the third week of memantine.

Opioid dosage (mg) was also constant in week three; the patient received 10 mg
in five of the seven days (Figure 25).
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4.1.1.5.2. Oxy/acet Dosage
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Figure 25: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Daily Opioid
Dosage (mg). Daily opioid dosages (mg) for each day of week three. ? = discrepancies.

Bowel movements for this week exhibited no unique characteristics (Figure 26)
but decreased slightly from the previous week (Figure 27).
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4.1.1.5.3. Bowel Movements
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Figure 26: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Daily Bowel
Movements. Daily bowel movements for each day of week three.

4.1.1.5.4. Overview through Week Three of Memantine
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Figure 27. Average Pain Scores, Average Opioid Dosage (mg) and Bowel
Movements per Week. Average weekly pain scores, opioid dosage (mg) and bowel
movements for the first five weeks of the study. arrow indicates when memantine was
first introduced.
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4.1.1.6. Week Four of Memantine

Data in the final week of memantine (10 mg a.m. & 10 mg p.m.) were constant
with previous trends. Afternoon pain scores were generally lower than the morning and
evening pain scores with an increase during the weekend (Figure 28).
4.1.1.6.1. Pain Scores
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Figure 28: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Daily Pain Scores.
Morning, afternoon and evening pain scores for each day over the fourth week of
memantine. (*) = missed memantine dose.

The average daily pain score for the fourth week stayed relatively constant again,
but were lower than that in week three of memantine (Figure 29).
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Average Daily Pain Scores

Week Four of Memantine (10 mg a.m. & 10
mg p.m.); Average Daily Pain Scores
8
7
6
5
4
3
2
1
0

4.7

5.0

4.3

5.7

6.3
5.0

5.0

Days of the Week

Figure 29: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Average Daily
Pain Scores. Averages of morning, afternoon and evening pain scores for each day over
the fourth week of memantine.

Opioid dosage (mg) was relatively consistent with the patient receiving either 5 or
10 mg throughout each day (Figure 30).
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4.1.1.6.2. Oxy/acet Dosage
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Figure 30: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Daily Opioid
Dosage (mg). Daily opioid dosage (mg) for each day of week four. ? = discrepancy.

Bowel movements increased during week four of memantine (Figure 31).
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4.1.1.6.3. Bowel Movements
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Figure 31: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Daily Bowel
Movements. Daily bowel movements for each day of week four.
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4.1.1.6.4. Overview through Week Four of Memantine
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Figure 32. Average Pain Scores, Average Opioid Dosage (mg) and Bowel
Movements per Week. Average weekly pain scores, opioid dosage (mg) and bowel
movements for each week of the study. Arrow indicates when memantine was first
introduced.

4.1.1.7. In-depth Overview of Study Subject M-01-B

When compiling data from all six weeks of the study, trends were easier to
observe. Average morning pain scores per week showed a decrease as the memantine
dosage increased (Figure 33).
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4.1.1.7.1. Pain Scores:
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Figure 33. Average Morning Pain Score Per Week. Average weekly morning pain
scores for each week of the study. Arrow indicates when memantine was first introduced.

The largest reduction in average pain score was in the afternoon (Figure 34).
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Figure 34. Average Afternoon Pain Score Per Week. Average weekly afternoon pain
scores for each week of the study. Arrow indicates when memantine was first introduced.

Average evening pain scores were similar to average morning reports, i.e.
approximately the same values but still a noticeable decrease from the first week to the
last (Figure 35).
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Figure 35. Average Evening Pain Score Per Week. Average weekly evening pain
scores for each week of the study. Arrow indicates when memantine was first introduced.

The overall average pain scores per week decreased from week to week as the
dosage of memantine increased (Figure 36).
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Figure 36. Average Pain Score Per Week. Average weekly pain scores for each week
of the study. Arrow indicates when memantine was first introduced.

There was a 2.3 pain score decrease from week one to week six. Opioid dosage
(mg) over the six weeks fluctuated slightly, however, there was a 3.5 mg decrease from
week one to week six (Figure 37).
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4.1.1.7.2. Oxy/acet Dosage
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Figure 37. Average Opioid Dosage (mg) per Day per Week. Average weekly opioid
dosage (mg) per day for each week of the study. Arrow indicates when memantine was
first introduced.

The average bowel movements did not show an increase over the six weeks of the
study (Figure 38). Week six average bowel movements were higher due to the one day
where the patient recorded five bowel movements.
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4.1.1.7.3. Bowel Movements
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Figure 38. Bowel Movements per Week. Bowel movements for each week of the study.
Arrow indicates when memantine was first introduced.

4.1.2. Study Subject F-01-R:

This patient was a good candidate for this study because she was taking 4 mg
hydromorphone, prn, every eight hours quaque octava hora (q8) for joint pain from a
motor vehicle accident decades ago; she was riding on her bike and was hit by a car. She
presented with antalgic gait including pain when turning and the feeling of ―walking
through molasses‖. This patient also experiences pain in the middle of the night, and
stated that her joint pain appears to be weather-related. The weather that affects this
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patient the most are rainy days and when the seasons are changing that brings along a
barometric alteration. She also stated that she takes gabapentin 600 mg – 900 mg up to
four times per day for restless leg, meclizine 50 mg per day for dizziness, Cymbalta 30
mg per day for depression, Atorvastatin 20 mg per day to lower cholesterol,
Hydrochlorothiazide (HCTZ) 25 mg per day to treat edema and metoprolol 50 mg per
day to treat angina.

4.1.2.1. Pre-Memantine Phase

Over the two week pre-memantine phase, this patient experienced consistent pain
scores in the morning, evening and afternoon. Her morning pain scores were all 5 or 6
(Figure 39), afternoon pain scores were mostly 6 and 7, with only two pain scores of 8
(Figure 40), and evening pain scores were all 8 with one night being a 9 (Figure 41).
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4.1.2.1.1. Pain Scores:
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Figure 39: Pre-Memantine Phase; Daily Morning Pain Scores. Daily morning pain
scores over the two week pre-memantine phase.

58

Daily Afternoon Pain Scores

Pre-Memantine Phase; Afternoon Pain
Scores
9
8
7
6
5
4
3
2
1
0

8
7

8

7
6

7

7

7

7

7

6

6

Days of the Week

Week 1

7

6

Week 2

Figure 40: Pre-Memantine Phase; Daily Afternoon Pain Scores. Daily afternoon pain
scores over the two week pre-memantine phase.
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Figure 41: Pre-Memantine Phase; Daily Evening Pain Scores. Daily evening pain
scores over the two week pre-memantine phase. * = patient not able to rest all day.
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The trend observed from the two week pre-memantine phase was that the patient
recorded an increased pain score as the day proceeded with the highest pain scores in the
evening (Figure 42).
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Figure 42: Pre-Memantine Phase; Daily Pain Scores. Daily morning, afternoon and
evening pain scores over the two week pre-memantine phase.

However when comparing the average daily pain score for each day of the prememantine phase, the average did not go lower than 6.3 or higher than a 7.3 (Figure 43).
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Figure 43: Pre-Memantine Phase; Average Daily Pain Scores. Averages of Morning,
Afternoon and Evening pain scores for each day over the two week pre-memantine phase.

The amount of hydromorphone consumed by this patient remained consistent with
12 mg total each day, except for one when the patient overslept and missed a
hydromorphone dose in the morning (Figure 44).

61

4.1.2.1.2. Hydromorphone Dosage
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Figure 44: Pre-Memantine Phase; Daily Opioid Dosage (mg). Daily opioid dosages
(mg) for each day over the two week pre-memantine phase. * = patient overslept and
missed a usual dose.

Bowel movements were unremarkable with only one bowel movement every
couple of days (Figure 45).
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4.1.2.1.3. Bowel Movements
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Figure 45: Pre-Memantine Phase; Daily Bowel Movements. Daily bowel movements
for each day over the two week pre-memantine phase.
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4.1.2.1.4. Overview of Pre-Memantine Phase
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Figure 46. Average Pain Scores, Average Opioid Dosage (mg) and Bowel
Movements per Week. Average weekly pain scores, average opioid dosage (mg) and
bowel movements for the first two weeks of the study.

4.1.2.2. Week One of Memantine

Daily pain scores for morning, afternoon and evening for the first week of
memantine (5 mg a.m.) showed a trend of the morning and afternoon being 6 with a
slight increase in the evening to pain scores of 7 and 8 (Figure 47).
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Figure 47: Week One of Memantine (5 mg a.m.); Daily Pain Scores. Morning,
afternoon and evening pain scores for each day over the first week of memantine.

Compared to the pre-memantine phase data, she had on average a reduction in
pain score at all times of the day. It also decreased (Figure 48) when compared to the prememantine phase data.
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Figure 48: Week One of Memantine (5 mg a.m.); Average Daily Pain Scores.
Averages of morning, afternoon and evening pain scores for each day over the first week
of memantine.

For week one of memantine the average daily pain score was either 6.3 or 6.7,
whereas during the pre-memantine phase, there were a few days that reached a pain score
of 7.3. However, daily opioid dosage (mg) remained constant at 12 mg (Figure 49).
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4.1.2.2.2. Hydromorphone Dosage

Daily Opioid Dosage (mg)

Week One of Memantine (5 mg a.m.);
Opioid Dosage (mg)
14

12

12

12

12

12

12

12

12
10
8
6
4
2
0

Days of the Week

Figure 49: Week One of Memantine (5 mg a.m.); Daily Opioid Dosage (mg). Daily
opioid dosages (mg) for each day of the first week of memantine.

Daily bowel movements did decrease slightly (Figure 50) from three bowel
movements per week during the pre-memantine phase to two for the first week of
memantine.
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4.1.2.2.3. Bowel Movements
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Figure 50: Week One of Memantine (5 mg a.m.); Daily Bowel Movements. Daily
bowel movements for each day of the first week of memantine.
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4.1.2.2.4. Overview through Week One of Memantine
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Figure 51. Average Pain Scores, Average Opioid Dosage (mg) and Bowel
Movements per Week. Average weekly pain scores, average opioid dosage (mg) and
bowel movements for the first three weeks of the study. Arrow indicates when
memantine was first introduced.

4.1.2.3. Week Two of Memantine

In daily pain scores for morning, afternoon and evening for the second week of
memantine (5 mg a.m. & 5 mg p.m.) there was a trend of the first two with a score of 6;
there were two instances where a pain score of 8 was recorded in the afternoon. Evening
pain scores were almost all 7 (Figure 52).
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Figure 52: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Daily Pain Scores.
Morning, Afternoon and evening pain scores for each day over the second week of
memantine. Increased afternoon pain scores due to weather-related neck pain.

When observing the average daily pain score over each day of week two of
memantine and comparing it to data from week one, there were more averages of 6.3,
however, one day it was a 7.0 (Figure 53).
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Figure 53: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Average Daily Pain
Scores. Averages of morning, afternoon and evening pain scores for each day over the
second week of memantine.

Daily opioid dosages (mg) for the second week of memantine dropped due to the
patient taking one less hydromorphone on Thursday, Friday and Saturday (Figure 54).
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4.1.2.3.2. Hydromorphone Dosage
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Figure 54: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Daily Opioid Dosage
(mg). Daily opioid dosages (mg) for each day of the second week of memantine.

Bowel movements for this week showed no special characteristics (Figure 55) but
decreased by a factor of 0.1 when compared to the pre-memantine phase (Figure 56).
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4.1.2.3.3. Bowel Movements
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Figure 55: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Daily Bowel
Movements. Daily bowel movements for each day of the second week of memantine.
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4.1.2.3.4. Overview through Week Two of Memantine
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Figure 56. Average Pain Scores, Average Opioid Dosage (mg) and Bowel
Movements per Week. Average weekly pain scores, average opioid dosage (mg) and
bowel movements for the first four weeks of the study. Arrow indicates when memantine
was first introduced.

4.1.2.4. Week Three of Memantine

When looking at daily pain scores for morning, afternoon and evening for the
third week of memantine (10 mg a.m. & 5 mg p.m.) there was a decreasing trend with
mid-week stabilization (Figure 57).
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Figure 57: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Daily Pain Scores.
Morning, afternoon and evening pain scores for each day over the third week of
memantine.

Monday was the worst day with a pain score of 9 recorded all day. From Tuesday
through Saturday the patient had an average daily pain score of 6, with a decrease to a
pain score of 5 on Sunday (Figure 58).
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Average Daily Pain Scores

Week Three of Memantine (10 mg a.m. & 5
mg p.m.); Average Daily Pain Scores
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Figure 58: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Average Daily
Pain Scores. Averages of morning, afternoon and evening pain scores for each day over
the third week of memantine. Patient describes the highest pain score is due to weather.

This decrease in pain score was accompanied by a reduction in hydromorphone
i.e., 4 mg less each day (Figure 59).
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4.1.2.4.2. Hydromorphone Dosage

Week Three of Memantine (10 mg
a.m. & 5 mg p.m.); Opioid Dosage (mg)
Opioid Dosage (mg)
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Figure 59: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Daily Opioid
Dosage (mg). Daily opioid dosages (mg) for each day of the third week of memantine.

Bowel movements stayed consistent with only two bowel movements this week
(Figure 60), although the average bowel movements per day per week have only
decreased by a factor of 0.1 (Figure 61).
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4.1.2.4.3. Bowel Movements

Daily Bowel Movements

Week Three of Memantine (10 mg a.m. &
5 mg p.m.); Daily Bowel Movements
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Figure 60: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Daily Bowel
Movements. Daily bowel movements for each day of week three.
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4.1.2.4.4. Overview through Week Three of Memantine

Pain Score, Opioid Dosage (mg), Bowel
Movements

Average Pain Scores, Average Opioid Dosage
(mg) and Bowel Movements per Week
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Figure 61. Average Pain Scores, Average Opioid Dosage (mg) and Bowel
Movements per Week. Average weekly pain scores, average opioid dosage (mg) and
bowel movements for the first five weeks of the study. Arrow indicates when memantine
was first introduced.

4.1.2.5. Week Four of Memantine:

In the final week, of memantine (10 mg a.m. & 10 mg p.m.) there was an
improvement in morning pain scores, i.e., recorded pain scores were 5 for each day;
afternoon and evening pain scores stayed relatively consistent from the previous week
(Figure 62).
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4.1.2.5.1. Pain Scores

Week Four of Memantine (10 mg a.m.
& 10 mg p.m.); Daily Pain Scores
Daily Pain Scores
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Figure 62: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Daily Pain Scores.
Morning, afternoon and evening pain scores for each day over the fourth week of
memantine.

The average daily pain score for the fourth week were relatively the lowest of the
whole study, i.e., five out of seven days the patient had an average pain score of only 5.7
(Figure 63).
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Average Daily Pain Scores

Week Four of Memantine (10 mg a.m. & 10
mg p.m.); Average Daily Pain Scores
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Figure 63: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Average Daily
Pain Scores. Averages of morning, afternoon and evening pain scores for each day over
the fourth week of memantine.

Opioid dosage (mg) decreased further in that the patient needed to take only two 4
mg hydromorphone every day except for Easter Sunday due to lack of rest time (Figure
64).
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4.1.2.5.2. Hydromorphone Dosage

Week Four of Memantine (10 mg a.m.
& 10 mg p.m.); Opioid Dosage (mg)
Opioid Dosage (mg)
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Figure 64: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Daily Opioid
Dosage (mg). Daily opioid dosage for each day of week four.

Even with a decreased hydromorphone dose, pain scores continued to decrease.
Bowel movements stayed consistent during week four of memantine (Figure 65).
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4.1.2.5.3. Bowel Movements

Week Four of (10 mg a.m. & 10 mg
p.m.); Daily Bowel Movements
Bowel Movements
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Figure 65: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Daily Bowel
Movements. Daily bowel movements for each day of week four.

She stated that the only side effect was constipation, but bowel movements
decreased by a factor of only 0.1 per day per week. (Figure 66).
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4.1.2.5.4. Overview through Week Four of Memantine

Pain Score, Opioid Dosage (mg), Bowel
Movements

Average Pain Scores, Average Opioid Dosage
(mg) and Bowel Movements per Week
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Figure 66. Average Pain Scores, Average Opioid Dosage (mg) and Bowel
Movements per Week. Average weekly pain scores, average opioid dosage (mg) and
bowel movements for each week of the study. Arrow indicates when memantine was first
introduced.

4.1.2.6. In-depth Overview of Study Subject F-01-R:

When compiling all data from the six weeks of the study trends are easier to
observe. The average morning pain scores per week actually increased as the memantine
dosage increased except for the last week when it was the lowest of the entire study
(Figure 67).
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4.1.2.6.1. Pain Scores

Average Morning Pain Scores Per
Week
Average Morning Pain Scores
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Figure 67. Average Morning Pain Score Per Week. Average weekly morning pain
scores for each week of the study. Arrow indicates when memantine was first introduced.

Average afternoon pain scores decreased as memantine dosage was increased;
they moved from an average of 6.9 during the pre-memantine phase to 6.1 (Figure 68).
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Average Afternoon Pain Scores

Average Afternoon Pain Scores Per
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Figure 68. Average Afternoon Pain Score Per Week. Average weekly afternoon pain
scores for each week of the study. Arrow indicates when memantine was first introduced.
The largest reduction in pain score was the average evening result; it decreased
from 8.1 to 6.6 (Figure 69).
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Figure 69. Average Evening Pain Score Per Week. Average weekly evening pain
scores for each week of the study. Arrow indicates when memantine was first introduced.
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Overall average pain scores per week decreased from week to week as memantine
dosage was raised (Figure 70).
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Figure 70. Average Pain Score Per Week. Average weekly pain scores for each week
of the study. Arrow indicates when memantine was first introduced.

The patient was at an average pain score of 6.9 during the pre-memantine phase
but dropped to 5.9 after the fourth week of memantine. Although this is only a decrease
in pain score by a factor of 1, the patient was taking less of her opioid. Opioid dosage
(mg) over the six weeks decreased from an average of 12 mg to an average of 8.6 mg
(Figure 71).
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4.1.2.6.2. Hydromorphone Dosage

Average Opioid Dosage (mg) Per Week
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Figure 71. Average Opioid Dosage (mg) per Day per Week. Average weekly opioid
dosage (mg) per day for each week of the study. Arrow indicates when memantine was
first introduced.

The number of bowel movements did not show an increase over the six weeks of
the study (Figure 72).
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4.1.2.6.3. Bowel Movements

Bowel Movements per Week
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Figure 72. Bowel Movements per Week. Average bowel movements per day for each
week of the study. Arrow indicates when memantine was first introduced.
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Chapter 5

DISCUSSION

This pilot study demonstrated trends of positive effectivness of memantine
although there were only a limited number of patients. While pateints can have different
etiologies of pain, opioids work by targeting the μ-receptor, a sub-class of opioid receptor
that is anti-nociceptive, thus making patients taking this medication comparable. The type
of opioid medication used by each patient was different, however, the similarities
between oxy/acet and hydromorphone made them suitable medications for this study.
They mainly work on the μ1 and μ2 receptors. The former, when activated, is responsible
for supraspinal analgesia whereas activation of the latter produces spinal analgesia,
respiratory depression and constipation [10]. Memantine reduces glutamate activity at
the NMDA receptor, and therefore has been shown to reduce pain. One mechanism of
pain transmission involves glutamate activating the NMDA receptor, causing an influx of
calcium ions into the post-synaptic neuron, making it more sensitive and more easily
depolarized; adding memantine reduces calcium flow from excess glutamate, reducing
the pain signal.
Oxycodone and hydromorphone are prescription opioids. Oxycodone is the main
ingredient in Percocet® along with acetaminophen; brand names for hydromorphone are
Dilaudid® and Exalgo®. Oxycodone and hydromorphone have similar properties; both
can be administered in tablet form or available as a liquid. They are ideal for patients that
have been taking opioids for an extended period of time and can benefit from a higher,
controlled dose due to the fact that both are also available in extended-release forms.
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However hydromorphone is stronger than oxycodone and are often prescribed for more
severe pain that stems from surgery, broken bones, and cancer [21].
Dosage requirements for these drugs depend on a few factors. Elements that
control the dosages are whether the drugs are in tablet form or liquid form, due to the
liquid form having a faster absorption rate, type of pain, source of pain, and if the patient
is in need of immediate-release or extended-release. If tolerance develops, both
oxycodone and hydromorphone strength can be increased. Since cross-tolerance is
incomplete among opioids, a common practice for physicians is to switch the type of
opioid the patient is taking to extended-release if they have been on that drug for a long
time with increasing dosages [21].
Side effects for each drug are similar due to similar shared properties. However,
since hydromorphone is a more potent drug, side effects experienced when taking this
drug can be more severe. The most common severe side effects for both of these drugs
are shallow or light breathing, constipation (more severe with extended-release
hydromorphone), drowsiness, dizziness and nausea. Less common severe side effects
include respiratory depression, seizures, hallucinations and ataxia. Side effects that are
relatively exclusive to hydromorphone when compared to oxycodone are heart
palpitations, respiratory complications and skin rashes. It is recommended to avoid
driving while taking these drugs due to the fact that both reduce judgment and physical
skills. Withdrawal symptoms are also very likely if one was to suddenly stop taking the
medication after a long-term use; they include gastrointestinal complications, cramping,
nausea, depression and agitation. It is recommended to taper off the medication slowly.
On the other end of the spectrum, both drugs can lead to overdose if too much is taken. A
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child can have a fatal overdose on just one extended-release hydromorphone tablet due to
high potency [21].
Hydromorphone has a black box warning on the label. This means that research
has proven it can have serious and even life-threatening side effects. Respiratory
depression causes the most concern. In addition, hydromorphone can cause hypotension.
Oxycodone and hydromorphone can enhance the depressant effects of alcohol; both can
also cause gastrointestinal complications such as nausea, vomiting, constipation, loss of
appetite.
Potential side effects of memantine (Namenda®) with an incidence greater than
5% are confusion (6%), dizziness (7%) and headache (6%) [4]. In placebo-controlled
trials in which dementia patients received doses of memantine up to 20 mg/day, the
likelihood of discontinuation because of an adverse event was the same in the memantine
group as in the placebo group, i.e. <1% [4].
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Table 1: Adverse Events Reported in Controlled Clinical
Trials in at Least 2% of Patients Receiving Namenda and
at a Higher Frequency than Placebo-treated Patients. [4]
Body System
Adverse Event
Body as a Whole
Fatigue
Pain
Cardiovascular System
Hypertension
Central and Peripheral
Nervous System
Dizziness
Headache
Gastrointestinal System
Constipation
Vomiting
Musculoskeletal System
Back pain
Psychiatric Disorders
Confusion
Somnolence
Hallucination
Respiratory System
Coughing
Dyspnea

Placebo
(N = 922)
%

Namenda
(N = 940)
%

1
1

2
3

2

4

5
3

7
6

3
2

5
3

2

3

5
2
2

6
3
3

3
1

4
2

5.1. Study Patient M-01-B
The first nursing home patient to complete this study was a 79 year-old male,
taking oxy/acet for a pressure ulcer, phantom pain and PEG-tube discomfort. There were
some small reductions in all measurements without the addition of memantine; this may
have been to an expectation (mindset) that analgesia was going to occur as a result of
being in the study [3]. Therefore, it was difficult to determine how much it contributed to
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reducing parameters of this patient. However, some trends were observed over the
remaining four weeks when memantine was administered.
Evaluation of daily morning, afternoon and evening pain scores for the first week
of memantine (5 mg a.m.), showed that the former was lower after taking 5 mg of
memantine in the morning. There was an anomaly; it occurred on the Friday of the first
week of memantine (*) (Figure 13). The patient was taken to the hospital Thursday night
because his PEG tube came out and it had to be replaced immediately. Due to the pain in
his feet, it is hard for this patient to walk and he relies on a wheel chair to get around. He
spent over six hours waiting in the hospital to be treated. The tape that the physicians
used pulled his skin causing a rash and increased irritation and pain. The patient did not
take an oxy/acet at the hospital because he did not want to stay there over-night; he just
endured the pain. This likely caused pain scores to become higher on Friday when he
returned to the nursing home.
Two noticeable differences were Saturday and Sunday of the third week of
memantine, where pain scores were slightly elevated (Figure 23). This may have been
due to the fact that weekend nurses are different than those on staff during the week; the
former group may not know the patient as well. Since this group is changing weekend by
weekend, they have less experience with the patient and did not recognize his situation at
a deeper, meaningful clinical level. This may have led to the patient to not get his
medication as quickly, resulting in increased pain.
Bowel movements increased during the final week of memantine. This may be
attributed to the fact that his diet mainly consists of pureed food due to his PEG tube and
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on Friday of that week he ate a piece of meatloaf by mouth that he received from another
patient; his gastrointestinal tract may have not been able to handle it (Figure 32).
This patient decided not to continue memantine medication after the study was
completed, due to the fact that he did not notice a difference in his way of life. However,
with data collected from this patient, it was evident that his pain score decreased
dramatically over the six-week study. Opioid dosage also decreased but may be attributed
to anomalies that occurred during the study. Bowel movements fluctuated and did not
show a certain trend.

5.2. Study Patient F-01-R

The second patient that completed this study was a female office-out patient who
is 69 years old, taking hydromorphone for joint pain and altered gait.
The Sunday of the second week of the pre-memantine phase there was increase in
pain score likely due to the patient not being able to rest because she was busy with
friends and family (Figure 42). There was an increase in opioid dosage from week one of
the pre-memantine phase to the second week due to a missed dose in the first week.
However, instead of doubling up the dosage later, or taking the missed dosage too close
to the second dose, the patient decided to refrain from taking the first one, resulting in a
lower average for the first week (Figure 44).
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This patient described significant improvement during this first week of
memantine and stated that she ―felt great‖. She now wanted to participate in activities
more of the time instead of always wanting to lay down to rest. F-01-R stated her pain
was less in the evening (Figure 47), with less fatigue, more clear-headedness, more
strength in her lower extremity, being able to sit up and stand faster after being seated for
a while, less hip pain, and having a more positive attitude. She also recorded taking 25
mg less meclizine during this week (prescribed for her dizziness) and stated that no other
drug has made her feel this great after taking it.
Sunday of the second week of memantine was another busy day for the patient
where she was unable to rest as much as usual. This likely caused her pain scores to be
slightly increased for that day (Figure 52). The patient started to decrease the amount of
opioid she was taking this week and was able to take one 4 mg hydromorphone less on
Thursday, Friday and Saturday (Figure 54). Although, there was not a decrease in
average pain score, the patient experienced no increase in pain when taking less opioid
along with memantine. At the end of the second week she described some dizziness and
nausea, but attributed those symptoms to the re-occurring neck pain, concluding that they
are nothing new and thus unrelated to memantine. This patient also noted that she still felt
as if memantine was giving her a clearer head and the ability to feel pain differently such
that she was able to isolate the exact location of the pain, instead of her whole body being
in pain.
F-01-R described the third week of memantine as her best at that point in the
study, and was amazed at how well she was feeling. All doses of gabapentin, meclizine
and hydromorphone had decreased. Gabapentin was reduced from 600 mg, four times a
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day to 300 mg three times per day, meclizine from 50 mg to 25 mg, and hydromorphone
from 12 mg per day to 8 mg per day. Monday was the worst day with a pain score of 9
recorded at each point (Figure 58). The patient attributed this to the weather and the fused
vertebrae in her neck. However, after taking the first 10 mg dose of memantine and
waking up the next day, the patient felt like she had a ―make-over‖, every part of her
body felt great. There was a decrease in pain score throughout the week, along with a
decrease in hydromorphone dose (Figure 59). However, even with a decrease in
hydromorphone, the patient described an increase in constipation which indicates that she
may be part of the 5% of patients that experience constipation while using memantine.
However, her bowel movements stayed constant at two per week during memantine
treatment which is only one lower than the pre-memantine phase baseline of three bowel
movements per week (Figure 61). This patient also reported no nausea or dizziness this
week and felt as though she wanted to get more involved in daily activities due to her
increase in well-being. Normally, F-01-R goes to bed early due to being in pain from the
day, but this week she stayed out at a concert until 10 o‘clock p.m. and was still alert. She
even felt well enough to wake up early and make it to morning Mass, whereas she would
usually wait to go to evening Mass.
Sunday of the fourth week of memantine there was an increase in pain score
likely due to it being a holiday event and the patient was not able to rest as much as usual
(Figure 62).
Pain score decreased slightly but was accompanied by a larger decrease in opioid
dosage. This showed that memantine had a definitive effect on the pain the patient was
experiencing. She also decided to continue with memantine after the study due to how
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well this medication made her feel. A follow- up on this patient revealed that she is
continuing to take only 8 mg of hydromorphone a day and her level of pain has stabilized
to slightly lower than before the study. She claims memantine is ―working better and
better each day”.
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Chapter 6
CONCLUSIONS
Adding memantine as an adjunct to daily opioid use in a chronic non-malignant
pain condition reduced overall pain scores in two patients, whereas a decrease in opioid
dosage and a slight reduction in bowel movements occurred only in one. It was the
intention to observe differences between males and females but since only one of each
gender was studied in the time-frame allotted for this study and the opioids were
different, it was not possible to evaluate any distinction. However, this pilot study
allowed insight to using memantine as an adjunct to treat chronic non-malignant pain
patients who take an opioid daily.
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Chapter 7
FUTURE DIRECTIONS
With the number of setbacks occurring at the beginning of this study, going
forward some aspects will need to be changed. Future work will require a more in-depth
review of the nursing homes to ensure that they have an adequate number of qualified
staff to handle patients that are involved in a clinical study, allowing for more accurate
data to be collected. In order to obtain a larger sample size, researchers could expand the
type of opioid medication the patients are using, instead of limiting the study to only two
types of opioids and expanding the amount of nursing home facilities or number of
medical offices with out-patients. This may increase the prospective patient size and
more patients may then be able to be recruited. With a larger patient sample size,
comparing how memantine could affect both males and females may become possible.
Other data that would be interesting to obtain from this study in the future would
be to try to observe if there is a certain amount of opioid dosage reduction in which it
would increase gastric motility, and also to try to observe any differences over a larger
age range. One thing to ask future test subjects would be to record any over-the-counter
medications they are using and identify if they cause additional gastrointestinal problems.
Researchers could then report if the complications from those medications are low or not
a factor.
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APPENDIX B: PAIN DIARY WEEK 1 (FRONT)

RESEARCH STUDY TO REDUCE OPIOID PAIN
MEDICATION USE IN PATIENTS BY ADDING MEMANTINE
PAIN AND MEDICATION DIARY- WEEK ONE
If you have any questions or concerns about this research,
please call Dr___________________ at
______________.
Before you turn to the next page, please answer these
questions:
DID ANYTHING HAPPEN TO YOU THIS WEEK THAT GAVE YOU MORE
PAIN?
___NO ___YES. IF ‗YES‘ PLEASE WRITE DOWN WHAT
HAPPENED.

DID YOU HAVE BAD EFFECTS FROM THE DRUGS DURING THIS
WEEK?
IF YOU DID, PLEASE WRITE DOWN WHAT THEY WERE.

APPENDIX B: PAIN DIARY WEEK 1 (BACK)
Patient Name (Please Print) _____________________________________________
Telephone:

Home: ____________________

Work ________________________
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APPENDIX B: PAIN DIARY WEEK 1 (BACK)

Week 1

How many
oxycodone or
oxycodone /
acetaminophen
tablets did you
take today?

What was
your pain
score this
morning?

What was
your pain
score this
afternoon?

What was
your pain
score
tonight?

How many
bowel
movements
did you have
today?

Day 1:

Day 2:

Day 3:

Day 4:

Day 5:

Day 6:

Day 7:

PAIN SCORE
___________________________________________________
0
1
2
3
4
5
6
7
8
9
10
I HAVE
THIS IS THE
NO PAIN
WORST PAIN
I EVER HAD

DATE COMPLETED _________________________ __
After you complete this page, please bring it with you to your weekly visit at the doctor’s office.

Thank you for joining our important study.
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APPENDIX B: PAIN DIARY WEEK 2 (FRONT)

RESEARCH STUDY TO REDUCE OPIOID PAIN
MEDICATION USE IN PATIENTS BY ADDING MEMANTINE
PAIN AND MEDICATION DIARY- WEEK TWO
If you have any questions or concerns about this research,
please call Dr___________________ at
______________.
Before you turn to the next page, please answer these
questions:
DID ANYTHING HAPPEN TO YOU THIS WEEK THAT GAVE YOU MORE
PAIN?
___NO ___YES. IF ‗YES‘ PLEASE WRITE DOWN WHAT
HAPPENED.

DID YOU HAVE BAD EFFECTS FROM THE DRUGS DURING THIS
WEEK?
IF YOU DID, PLEASE WRITE DOWN WHAT THEY WERE.

APPENDIX B: PAIN DIARY WEEK 1 (BACK)
Patient Name (Please Print) _____________________________________________
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APPENDIX B: PAIN DIARY WEEK 2 (BACK)

Week 2

How many
oxycodone or
oxycodone /
acetaminophen
tablets did you
take today?

What was
your pain
score this
morning?

What was
your pain
score this
afternoon?

What was
your pain
score
tonight?

How many
bowel
movements
did you have
today?

Day 1:

Day 2:

Day 3:

Day 4:

Day 5:

Day 6:

Day 7:

PAIN SCORE
___________________________________________________
0
1
2
3
4
5
6
7
8
9
10
I HAVE
THIS IS THE
NO PAIN
WORST PAIN
I EVER HAD

DATE COMPLETED _________________________ __
After you complete this page, please bring it with you to your weekly visit at the doctor’s office.

Thank you for joining our important study.
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APPENDIX B: PAIN DIARY WEEK 3 (FRONT)

RESEARCH STUDY TO REDUCE OPIOID PAIN
MEDICATION USE IN PATIENTS BY ADDING MEMANTINE
PAIN AND MEDICATION DIARY- WEEK THREE
If you have any questions or concerns about this research,
please call Dr___________________ at
______________.
Before you turn to the next page, please answer these
questions:
DID ANYTHING HAPPEN TO YOU THIS WEEK THAT GAVE YOU MORE
PAIN?
___NO ___YES. IF ‗YES‘ PLEASE WRITE DOWN WHAT
HAPPENED.

DID YOU HAVE BAD EFFECTS FROM THE DRUGS DURING THIS
WEEK?
IF YOU DID, PLEASE WRITE DOWN WHAT THEY WERE.

APPENDIX B: PAIN DIARY WEEK 1 (BACK)
Patient Name (Please Print) _____________________________________________
Telephone:

Home: ____________________

Work ________________________
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APPENDIX B: PAIN DIARY WEEK 3 (BACK)

Week 3

How many
oxycodone or
oxycodone /
acetaminophen
tablets did you
take today?

What was
your pain
score this
morning?

What was
your pain
score this
afternoon?

What was
your pain
score
tonight?

How many
bowel
movements
did you have
today?

Day 1:

Day 2:

Day 3:

Day 4:

Day 5:

Day 6:

Day 7:

PAIN SCORE
___________________________________________________
0
1
2
3
4
5
6
7
8
9
10
I HAVE
THIS IS THE
NO PAIN
WORST PAIN
I EVER HAD

DATE COMPLETED ___________________________
After you complete this page, please bring it with you to your weekly visit at the doctor’s office.

Thank you for joining our important study.
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APPENDIX B: PAIN DIARY WEEK 4 (FRONT)

RESEARCH STUDY TO REDUCE OPIOID PAIN
MEDICATION USE IN PATIENTS BY ADDING MEMANTINE
PAIN AND MEDICATION DIARY- WEEK FOUR
If you have any questions or concerns about this research,
please call Dr___________________ at
______________.
Before you turn to the next page, please answer these
questions:
DID ANYTHING HAPPEN TO YOU THIS WEEK THAT GAVE YOU MORE
PAIN?
___NO ___YES. IF ‗YES‘ PLEASE WRITE DOWN WHAT
HAPPENED.

DID YOU HAVE BAD EFFECTS FROM THE DRUGS DURING THIS
WEEK?
IF YOU DID, PLEASE WRITE DOWN WHAT THEY WERE.

APPENDIX B: PAIN DIARY WEEK 1 (BACK)
Patient Name (Please Print) _____________________________________________
Telephone:

Home: ____________________

Work ________________________
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APPENDIX B: PAIN DIARY WEEK 4 (BACK)

Week 4

How many
oxycodone or
oxycodone /
acetaminophen
tablets did you
take today?

What was
your pain
score this
morning?

What was
your pain
score this
afternoon?

What was
your pain
score
tonight?

How many
bowel
movements
did you have
today?

Day 1:

Day 2:

Day 3:

Day 4:

Day 5:

Day 6:

Day 7:

PAIN SCORE
___________________________________________________
0
1
2
3
4
5
6
7
8
9
10
I HAVE
THIS IS THE
NO PAIN
WORST PAIN
I EVER HAD

DATE COMPLETED ___________________________
After you complete this page, please bring it with you to your weekly visit at the doctor’s office.

Thank you for joining our important study.
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APPENDIX B: PAIN DIARY WEEK 5 (FRONT)

RESEARCH STUDY TO REDUCE OPIOID PAIN
MEDICATION USE IN PATIENTS BY ADDING MEMANTINE
PAIN AND MEDICATION DIARY- WEEK FIVE
If you have any questions or concerns about this research,
please call Dr___________________ at
______________.
Before you turn to the next page, please answer these
questions:
DID ANYTHING HAPPEN TO YOU THIS WEEK THAT GAVE YOU MORE
PAIN?
___NO ___YES. IF ‗YES‘ PLEASE WRITE DOWN WHAT
HAPPENED.

DID YOU HAVE BAD EFFECTS FROM THE DRUGS DURING THIS
WEEK?
IF YOU DID, PLEASE WRITE DOWN WHAT THEY WERE.

APPENDIX B: PAIN DIARY WEEK 1 (BACK)
Patient Name (Please Print) _____________________________________________
Telephone:

Home: ____________________

Work ________________________
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APPENDIX B: PAIN DIARY WEEK 5 (BACK)

Week 5

How many
oxycodone or
oxycodone /
acetaminophen
tablets did you
take today?

What was
your pain
score this
morning?

What was
your pain
score this
afternoon?

What was
your pain
score
tonight?

How many
bowel
movements
did you have
today?

Day 1:

Day 2:

Day 3:

Day 4:

Day 5:

Day 6:

Day 7:

PAIN SCORE
___________________________________________________
0
1
2
3
4
5
6
7
8
9
10
I HAVE
THIS IS THE
NO PAIN
WORST PAIN
I EVER HAD

DATE COMPLETED _________________________ __
After you complete this page, please bring it with you to your weekly visit at the doctor’s office.

Thank you for joining our important study.
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APPENDIX B: PAIN DIARY WEEK 6 (FRONT)

RESEARCH STUDY TO REDUCE OPIOID PAIN
MEDICATION USE IN PATIENTS BY ADDING MEMANTINE
PAIN AND MEDICATION DIARY- WEEK SIX
If you have any questions or concerns about this research,
please call Dr___________________ at
______________.
Before you turn to the next page, please answer these
questions:
DID ANYTHING HAPPEN TO YOU THIS WEEK THAT GAVE YOU MORE
PAIN?
___NO ___YES. IF ‗YES‘ PLEASE WRITE DOWN WHAT
HAPPENED.

DID YOU HAVE BAD EFFECTS FROM THE DRUGS DURING THIS
WEEK?
IF YOU DID, PLEASE WRITE DOWN WHAT THEY WERE.

APPENDIX B: PAIN DIARY WEEK 1 (BACK)
Patient Name (Please Print) _____________________________________________
Telephone:

Home: ____________________

Work ________________________
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APPENDIX B: PAIN DIARY WEEK 6 (BACK)

Week 1

How many
oxycodone or
oxycodone /
acetaminophen
tablets did you
take today?

What was
your pain
score this
morning?

What was
your pain
score this
afternoon?

What was
your pain
score
tonight?

How many
bowel
movements
did you have
today?

Day 1:

Day 2:

Day 3:

Day 4:

Day 5:

Day 6:

Day 7:

PAIN SCORE
___________________________________________________
0
1
2
3
4
5
6
7
8
9
10
I HAVE
THIS IS THE
NO PAIN
WORST PAIN
I EVER HAD

DATE COMPLETED ___________________________
After you complete this page, please bring it with you to your weekly visit at the doctor’s office.

Thank you for joining our important study.
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APPENDIX C: M INI M ENTAL STATE EXAMINATION QUESTIONNAIRE
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APPENDIX C: M INI M ENTAL STATE EXAMINATION QUESTIONNAIRE
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APPENDIX D: PATIENT STUDY SCHEDULE

Memantine

PART 1 Week 1

None

Pain
and
Medication
Diary
Daily

Week 2

None

Daily

Week 3

5 mg Memantine AM
--------------Nothing PM

Daily

Week 4

5 mg Memantine AM
+
5 mg memantine PM

Daily

Week 5

10 mg Memantine AM
+
5 mg memantine PM

Daily

Week 6

10 mg Memantine AM
+
10 mg memantine PM

Daily

PART 2
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